==== Front Med Sci MonitMed. Sci. MonitMedical Science MonitorMedical Science Monitor : International Medical Journal of Experimental and Clinical Research1234-10101643-3750International Scientific Literature, Inc. 3006890110.12659/MSM.908382908382Clinical ResearchClinical Therapeutic Effect of Naloxone Combined with Hemodialysis on Acute Severe Alcoholism Wang Guixia 1ABDELi Zhenhe 2ACEFLi Min 2BCDFLiu Shanmei 1BCDFShan Timei 2ABDELiu Jiaqiang 1CDEFZhang Yuliang 1ABDF 1 Department of Hemodialysis, Linyi City Yishui Central Hospital, Linyi, Shandong, P.R. China 2 Department of Emergency, Linyi City Yishui Central Hospital, Linyi, Shandong, P.R. ChinaCorresponding Author: Zhenhe Li, e-mail: zhenheli123@sohu.comA Study Design B Data Collection C Statistical Analysis D Data Interpretation E Manuscript Preparation F Literature Search G Funds Collection 2018 02 8 2018 24 5363 5367 05 12 2017 20 3 2018 © Med Sci Monit, 20182018This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)Background The aim of this research was to investigate the treatment effect of naloxone combined with hemodialysis on acute severe alcoholism. Material/Methods We included 36 patients treated with naloxone combined with hemodialysis in Group I and 34 patients treated with naloxone without hemodialysis in Group II. The Glasgow coma scale (GCS) score, the consciousness recovery time, alanine amino transferase (ALT) level, and complications were analyzed. Results Mean GCS score in Group I was higher than that in Group II, with a significant difference (P<0.05). The consciousness recovery time in Groups I and II were 3.0±0.8 h and 6.9±2.1 h, respectively, with a significant difference (P<0.05). After naloxone treatment and hemodialysis, the ALT level in Group I was lower than that in Group II (P<0.05). Moreover, the incidence of hepatic and renal function damages in Group I was smaller than that in Group II (P<0.05). Only 1 patient in Group I developed pneumonia, which was fewer than that in Group II, with a significant difference (P<0.05). Conclusions Naloxone combined with hemodialysis effectively reduces the central inhibition of alcohol, shortens consciousness recovery time, improves respiratory and cardiovascular function, decreases hepatic and renal function damages, and reduces the incidence of complications. MeSH Keywords Acute DiseaseAlcoholismGlasgow Coma ScaleHemodialysis Units, HospitalNaloxone ==== Body Background Acute severe alcoholism (ASA) is a disease caused by the ingestion of large amounts of alcohol. It can cause a variety of clinical manifestations involving many organs, which can induce behavioral, cardiac, gastrointestinal, pulmonary, neurological, and metabolic dysfunctions [1]. ASA is also a medical emergency that can be life-threatening due to respiratory depression and inhalation of vomit [2]. Despite laws, policies, and health education efforts seeking to control daily alcohol intake levels, ASA remains common in China and around the world. The opioid antagonist naloxone is a derivative of oxymorphone. There are many reports about naloxone in the treatment of ASA. It can reduce the level of β-endorphin in the brain and help patients regain consciousness. However, it may have a harmful effect on the cardiovascular system [3]. Recently, the mechanism of naloxone in ASA treatment has become increasingly clear [4]. Treatment with naloxone greatly helps in the recovery of patients by binding to reward-related regions of the brain [5]. Although it warrants further use in clinical therapy, naloxone is an antagonist of opioid receptors and plays a role in regulating cardiovascular and respiratory systems [6]. Naloxone does not produce secretions and it cannot effectively remove the metabolites of alcohol, leaving CO2 and H+ ions to be removed only by natural metabolism [7,8]. Hemodialysis is an important step of hemopurification, which removes metabolic waste through dialysate. Then, the purified blood is injected into the blood vessels [9]. It not only improve physiological and living qualities [10], but also effectively prevents death induced by circulatory and respiratory failures [11]. In the present study, patients in Group I received treatment with naloxone and hemodialysis, while patients in the control group (Group II) were only treated with naloxone. We compared these therapies to analyze the effect of hemodialysis on ASA and the effect of naloxone on ASA. Material and Methods Patients We enrolled 70 ASA patients with an average age of 33.6±7.2 who were admitted to our hospital from January 2014 to December 2016. This research was approved by the Ethics Committee of Linyi City Yishui Central Hospital. All patients had ingested 400–700 ml of high-concentration alcohol. At an average of about 2 hours after the ingestion, they were admitted to our hospital. Patients arrived in our hospital in unconscious state and many had vomited before becoming comatose. Physical examination demonstrated that all patients were in at least moderate-level coma, with Glasgow coma scale (GCS) score [12] lower than 8. Patients were breathing with snoring and apnea. They all had no reaction to painful stimuli, had slow pupillary light reflex, and lacked pathologic reflex. Alcohol concentration in the blood was more than 2500 mg/L and blood oxygen saturation was ≥90%. Most patients did not have a history of hypertension or cardiovascular, liver, or kidney diseases. Treatment for patients All patients were automatically treated with naloxone or naloxone combined with hemodialysis. There were 36 patients who received naloxone combined with hemodialysis treatment (Group I) and 34 patients received naloxone treatment without hemodialysis (Group II). All patients received basic treatment, including clean-out of vomitus, oxygen inhalation, warming, and fluid infusion. Patients in Group II were treated with 500 ml normal saline containing 0.2 mg naloxone and water-soluble vitamins and a 2000-ml glucose injection (5% glucose) by intravenous infusion and gastric mucosa-protective agents. In addition to these treatments, patients in Group I were also treated with hemodialysis. The initial velocity of the blood was 150 ml/min. If the vital signs of patients were improved 15 min later, the velocity was gradually increased to 500 ml/min for 3–4 h. Clinical observation Respiration, blood pressure, oxygen saturation, and heart rate were observed in real time during the treatment. After drug and hemodialysis treatments, consciousness recovery was observed and evaluated with GCS score, which helped us to estimate the treatment effects. The treatment was regarded as no effect at GCS <8 and significant treatment effect at GCS ≥12. The details are shown in Table 1. We performed routine assessment of blood, urine, hepatic and renal functions, myocardial enzyme, arterial blood gas, and alanine amino transferase (ALT) before and after the treatments. Consciousness recovery time and complications after the treatments were also analyzed. Statistical analysis Statistical analysis was performed with SPSS 21.0. GCS scores, consciousness recovery time, and ALT level are shown as mean ± standard deviation and were analyzed using the t test. Complications of ASA patients after the treatments were analyzed by chi-square test. There was a significant difference at P<0.05. Results Basic information Patients were divided into 2 groups and were given different treatments. In Group I, 36 patients were treated with naloxone combined with hemodialysis, and 34 patients treated with naloxone were in Group II. Results of statistical analysis showed that there were no significant differences in age, sex, volume of alcohol ingested, or the time from intoxication to admission at our hospital between the 2 groups (P>0.05) (Table 2). GCS score and clinical treatment effect After clinical treatment, the treatment effects in the 2 groups were estimated by GCS score. As shown in Table 3, mean GCS score in Group I was higher than that in Group II, with a significant difference (P<0.05). There were 21 patients with significant effect in Group I, which were more than in the control group (Group II). Moreover, the higher efficacy rate in Group I demonstrated that hemodialysis had a significant treatment effect (Table 3). Symptoms improvement After clinical treatment, all symptoms disappeared several hours later. However, there were also some differences between the 2 groups. The consciousness recovery time in Groups I and II were 3.0±0.8 h and 6.9±2.1 h, respectively, with a significant difference (P<0.05). After treatment, ALT level was remarkably changed, but there was no difference between the 2 groups before treatment (P=0.35). Nevertheless, ALT level in Group I after the treatment with naloxone and hemodialysis was lower than that in the control group after the treatment with naloxone, with a significant difference (P<0.05). This demonstrates that naloxone combined with hemodialysis can decrease ALT level and promote recovery of consciousness (Table 4). Complications after treatment Common complications of ASA were myocardial injury, hepatic and renal function damages, and pneumonia [13]. In this research, there was no difference in myocardial injury between the 2 groups (P=0.69). The incidence of hepatic and renal function damages in Group I was lower than that in the control group, with a significant difference (P<0.05). In addition, 1 patient suffered from pneumonia in Group I, which was fewer than that in the control group, with a significant difference (P<0.05) (Table 5). Discussion In the 19th century, alcoholism started being regarded as a disease in the broader sense, as a physical and mental disorder [14]. The metabolic effects of alcohol include decreased synthesis of albumin, in addition to decreased serum concentration of magnesium, calcium, and phosphate [15]. Due to the direct or indirect toxic action of alcohol, it decreases the absorption of folic acid and the production of red blood cells [16,17]. Metabolites of alcohol can act on opioid receptors in the cerebrum and regulate the brain condition from excitation to inhibition. Subsequently, the subcortical center, cerebellum, and vasoconstriction and respiratory center in the medulla oblongata are gradually damaged [18,19]. Thus, removing of metabolites of alcohol is very important in ASA treatment. Naloxone can play a major role in improving a patient’s condition [20], but it has a limited ability to remove alcohol metabolites, which can be addressed with the use of hemodialysis. In this research, patients in Group I were given hemodialysis treatment. Compared to the control group, GCS scores in Group I were significantly higher (P<0.05), which demonstrates that the treatment effect in Group I was better than that in the control group. Significant treatment effects were observed in 21 patients (58.33%) in Group I and 14 patients (41.18%) in Group II. Although there was no noticeable effect in 1 patient in Group I, he quickly recovered consciousness. Consciousness recovery time in Group I was 3.0±0.8 h, which was much shorter than in the control group. This might be related to the removing of alcohol metabolites. Hemodialysis can transfer alcohol metabolites to dialysate by ion-exchange, which can directly or indirectly influence the dopamine system and play a positive role in regulating the biological consequences of alcoholism [21]. Moreover, ALT level in Group I after treatment was remarkably lower than that in Group II (P<0.05), and the complications, including pneumonia (P<0.05) and hepatic and renal function damages (P<0.05), in Group I were significantly lower than in Group II. Thus, the synergistic effect of naloxone combined with hemodialysis was fully demonstrated. The main function of hemodialysis was to remove ethanol and alcohol metabolites and correct the acid-base balance to stabilize the environment. Naloxone is a specific antagonist of endogenous opioid substances, which can play a role in the combination of β-endorphin and intracranial opioid receptors and reduce the level of β-endorphin [22]. The combination of naloxone and hemodialysis can effectively shorten the ethanol removal time and overturn the central inhibitory effect of ethanol to improve respiratory function and circulation, as well as speeding the recovery of consciousness and reducing the occurrence of complications [23]. Conclusions Our results show the significant therapeutic effect of naloxone combined with hemodialysis. Hemodialysis can remove alcohol metabolites and regulate water and electrolyte disturbances [24], and naloxone can interrupt β-endorphin binding to opioid receptors [25]. The combination of naloxone and hemodialysis can effectively reduce central inhibition induced by alcohol, shorten the consciousness recovery time, improve respiratory and cardiovascular functions, decrease hepatic and renal function damages, and reduce the incidence of complications. Therefore, hemodialysis as an adjuvant therapy should be broadly applied in ASA treatment. Source of support: Departmental sources Conflict of interest None. Table 1 GCS score and treatment effect. Treatment effect GCS Symptom No effect <8 No pain reaction; slow pupillary light reflex; no pathologic reflex Effect 8≤ GCS <12 Deep slumber or light coma; eyes could open under a strong stimulation; could point out the localization of pain Significant effect ≥12 Sleepiness; could express with simple words GCS – glasgow coma scale. Table 2 Basic information of patients. The term “volume of alcohol” means the volume of alcohol absorbed by patients. The term “visiting time” means the time from alcoholism to visiting doctors. Terms Group I Group II P Number 36 34 Age 33.1±9.2 34.1±8.5 0.871 Gender Male 25 26 0.515 Female 11 8 Weight (kg) 66.0±11.20 64.50±12.35 0.374 Volume of alcohol (ml) 342±59.2 334±61.0 0.905 Visiting time (h) 2.10±0.85 2.15±0.90 0.765 The T-test method was used for the comparison between two groups in age, gender, weight, volume of alcohol and visiting time. There is no difference between two groups in these terms. Table 3 The GCS score and clinical treatment effect. Groups GCS (means) Significant effect Effect No effect Num. Rate (%) Num. Rate (%) Num. Rate (%) Group I 11.5±2.65 21 58.33 14 38.89 1 2.78 Group II 9.62±3.38 14 41.18 15 44.12 5 14.70 P 0.012 The statistical analysis of GCS score were performed with T-test. P<0.05 indicates a statistically significant difference. GCS – glasgow coma scale. Table 4 The consciousness recovery and ALT level of two groups. Group Consciousness recovery (h) ALT (U/L) Before treatment After treatment Group I 3.0±0.8 163.59±40.50 60.1±36.76 Group II 6.9±2.1 158.41±52.87 186.36±45.12 P 1.10×10−17 0.35 1.28×10−19 The statistical analysis of consciousness recovery time and ALT level were performed with T-test. P<0.05 indicates a statistically significant difference. ALT – alanine amino transferase. Table 5 Complications of ASA patients in two groups. Terms Group I Group II P Myocardial injury 3 2 0.69 Hepatic and renal function damage 2 10 8.1×10−3 Pneumonia 1 6 0.038 The statistical analysis of complications was performed with Chi-square test. P<0.05 indicates a statistically significant difference. ==== Refs References 1 Vonghia L Leggio L Ferrulli A Acute alcohol intoxication Eur J Intern Med 2008 19 561 67 19046719 2 Devi G Management of drug and alcohol withdrawal N Engl J Med 2003 349 405 7 author reply 405–7 3 Xuan HL Clinical observation of naloxone combined with xingnaojing injection in the treatment of 87 cases of acute severe alcoholism Contemporary Medine 2010 10 145 47 4 Tong W Wenli L Refreshing static joint curative effect observation of treatment of acute alcohol intoxication of naloxone Medicine & People 2014 3 045 5 Laukkanen V Karkkainen O Kautiainen H Decreased [3H] naloxone binding in the dentate gyrus of cloninger type 1 anxiety-prone alcoholics: A postmortem whole-hemisphere autoradiography study Alcohol Clin Exp Res 2015 39 1352 59 26147003 6 Dwyer K Walley AY Sorensen-Alawad A Opioid education and nasal naloxone rescue kits in the emergency department West J Emerg Med 2013 16 381 84 7 Salman S Buttigieg J Zhang M Nurse CA Chronic exposure of neonatal rat adrenomedullary chromaffin cells to opioids in vitro blunts both hypoxia and hypercapnia chemosensitivity J Physiol 2013 591 515 29 23148319 8 Salman S Buttigieg J Nurse CA Ontogeny of O2 and CO2//H+ chemosensitivity in adrenal chromaffin cells: role of innervation J Exp Biol 2014 217 673 81 24574383 9 Mori Y Toyoda M Hemodialysis apparatus and method for hemodialysis US Patent 2013 10 Suri RS Larive B Sherer S Risk of vascular access complications with frequent hemodialysis J Am Soc Nephrol 2013 24 498 505 23393319 11 Koo JR Kim JC Yoon JW Failure of continuous venovenous hemofiltration to prevent death in paraquat poisoning Am J Kidney Dis 2002 39 55 59 11774102 12 Hansen B Quick J Sinkovits E Smith JC Glasgow coma scale: How to improve and enhance documentation J Trauma Nurs 2014 21 122 24 quiz 125–26 24828774 13 Kasztelan-Szczerbinska B Surdacka A Slomka M Association of serum adiponectin, leptin, and resistin concentrations with the severity of liver dysfunction and the disease complications in alcoholic liver disease Mediators Inflamm 2013 2013 148526 24259947 14 Sabino KR Petroianu A Alberti LR Influence of the acute alcoholism on the phagocytic function of the mononuclear phagocytic system J Med Life 2011 4 421 23 22514578 15 Money SR Petroianu A Kimura K Jaffe BM Acute hypocalcemic effect of ethanol in dogs Alcohol Clin Exp Res 1989 13 453 56 2665562 16 Bjorneboe GE Bjorneboe A Johnsen J Calcium status and calcium-regulating hormones in alcoholics Alcohol Clin Exp Res 1988 12 229 32 2837104 17 Miljanovic B Dana R Sullivan DA Schaumberg DA Impact of dry eye syndrome on vision-related quality of life Am J Ophthalmol 2007 143 409 15 17317388 18 Bart G Kreek MJ Ott J Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden Neuropsychopharmacology 2005 30 417 22 15525999 19 Dai LF Observation of the clinical effect of naloxone joint Xingnaojing injection on treating acute severe alcoholism Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease 2013 21 128 29 20 Jeffcoate WJ Herbert M Cullen MH Prevention of effects of alcohol intoxication by naloxone Lancet 1979 2 1157 59 91889 21 Deehan GA Jr Hauser SR Wilden JA Elucidating the biological basis for the reinforcing actions of alcohol in the mesolimbic dopamine system: The role of active metabolites of alcohol Front Behav Neurosci 2015 7 104 22 Shi BQ Zhu H Liu CJ Naloxone clinical application Hebei Medicine 2003 25 702 [in Chinese] 23 Yang M Nursing care of acute alcoholism induced by naloxone in promoting awakening Chinese Journal of Misdiagnostics 2007 7 381 [in Chinese] 24 Ryu J Lim KH Ryu DR Two cases of methyl alcohol intoxication by sub-chronic inhalation and dermal exposure during aluminum CNC cutting in a small-sized subcontracted factory Ann Occup Environ Med 2016 28 65 27891239 25 Gaveriaux-Ruff C Opiate-induced analgesia: contributions from mu, delta and kappa opioid receptors mouse mutants Curr Pharm Des 2013 19 7373 81 23448470